Intravitreal Injections of rhuFab V2 in Combination With Visudyne in Subjects With Age Related Macular Degeneration (AMD)

Sponsor
Genentech, Inc.
Study ID
NCT00056823
Phase
PHASE1/PHASE2
Status
Completed

Conditions

  • Age-Related Maculopathy

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The primary purpose of this study is to determine if injections of rhuFab V2 into the eye in combination with verteporfin photodynamic therapy (PDT) is a safe and efficacious treatment for patients with age-related macular degeneration.

Key Dates

First listed
Mar 26, 2003
Start date
Mar 31, 2003
Status verified
Jun 2013
Completion
Dec 31, 2005

Study Design

Enrollment
168 participants
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT